Looking back, it almost seems like a dream. On Aug. 31, 2020, the U.S. had just surpassed six million COVID-19 cases, people were encouraged to wear masks and practice social distancing, and biopharma giant AstraZeneca had begun late-stage trials of its vaccine candidate. This was also the day that ...